DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study

Abstract Triplet DCF (docetaxel, cisplatin and 5-flurouracil) and doublet CP/CF (carboplatin and paclitaxel/cisplatin and 5-fluorouracil) regimens were prospectively evaluated in advanced squamous anal cell carcinoma (SCCA), and validated as standard treatments. Even though the high efficacy and goo...

Descripció completa

Dades bibliogràfiques

Autors principals:	Stefano Kim, Véronique Vendrely, Angélique Saint, Thierry André, Pauline Vaflard, Emmanuelle Samalin, Simon Pernot, Oliver Bouché, Mustapha Zubir, Jérôme Desrame, Christelle de la Fouchardière, Denis Smith, François Ghiringhelli, Angélique Vienot, Marion Jacquin, Elodie Klajer, Thierry Nguyen, Éric François, Julien Taieb, Karine Le Malicot, Dewi Vernerey, Aurélia Meurisse, Christophe Borg
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2023-07-01
Col·lecció:	Experimental Hematology & Oncology
Matèries:	Anal carcinoma Advanced Metastatic Chemotherapy Docetaxel
Accés en línia:	https://doi.org/10.1186/s40164-023-00413-2
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!